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Abstract
Purpose—Periodontitis, a chronic inflammatory response to pathogenic bacteria in the oral 
microbiome, is common among adults. It is associated with several medical conditions, including 
cardiovascular diseases, and potentially with esophageal, lung, oral and pancreatic cancer. One of 
the proposed mechanisms behind these associations is systemic inflammation, which has also been 
implicated in ovarian cancer etiology. The aim of this study was to evaluate association between 
ovarian cancer and periodontal bone loss.
Methods—The association between periodontal bone loss, a marker of periodontitis, and risk of 
epithelial ovarian cancer was estimated among 60,560 participants of the prospective Nurses’ 
Health Study using Cox proportional hazards analysis. Competing risks analysis was used to 
estimate association by histological subtype.
Results—We did not observe an increased risk of ovarian cancer among participants with 
periodontal bone loss (HR=0.86, 95% CI: 0.64–1.15). Among women younger than 69 years, 
periodontal bone loss was associated with a 40% (HR=0.60, 95% CI: 0.36–0.98) decreased 
ovarian cancer risk, while there was no association in women older than 69 (HR=1.09, 95% CI: 
0.75–1.58), although this difference did not reach statistical significance (p-heterogeneity=0.06). 
We observed a suggestive decreased risk for serous tumors (HR=0.76, 95% CI: 0.53–1.09). The 
number of natural teeth and root canals, other metrics of oral health, were not associated with 
ovarian cancer risk.
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Conclusion—Our results do not support an increased ovarian cancer risk in women with 
periodontal bone loss, however there was a significant decrease in risk in women younger than 69. 
Given the unexpected association between periodontal bone loss and ovarian cancer risk in 
younger women, further research is warranted.
Keywords
ovarian cancer; periodontitis; oral microbiome; cohort study
Introduction
Ovarian cancer is the fifth most common cause of cancer deaths in women and the deadliest 
of all gynecological cancers [1]. Although ovarian cancer has been extensively studied, its 
etiology is far from being fully elucidated. Several hypotheses have been proposed to 
explain ovarian cancer. While some risk factors, such as parity and use of oral 
contraceptives (OC), lessen the repeated damage and repair of ovarian epithelium associated 
with ovulation [2–4], other risk factors such as endometriosis, use of genital powder, and 
tubal ligation likely act through inflammatory pathways [5]. Furthermore, in a recently 
published study including participants from 3 prospective cohorts, women in the top quartile 
of CRP levels had a 53% increase in ovarian cancer risk compared to women in the bottom 
quartile [6].
Periodontitis is a chronic inflammatory disease of tooth supporting structures, affecting 47% 
of adults aged 30 years and older in the United States, leading to gradual loss of periodontal 
tissues including periodontal bone, and in aggressive and severe cases (5–10%) to tooth loss 
[7, 8]. Periodontitis is a chronic inflammatory response to pathogenic bacteria present in 
dental plaque [9]. It might lead to systemic inflammation, as suggested by increased blood 
levels of several inflammatory markers, such as C-reactive protein (CRP), IL-6 and TNF-α 
[10, 11] among patients with periodontitis. Periodontitis has been associated with several 
diseases, including cardiovascular diseases, psoriasis, diabetes mellitus, preterm birth, as 
well as with esophageal, lung, oral and pancreatic cancers [12–17].
We hypothesized that periodontitis and the associated inflammation may be associated with 
an increased risk of ovarian cancer. To our knowledge, no previous studies have evaluated 
this association. We investigated whether periodontal bone loss, a hallmark of periodontitis, 
was associated with epithelial ovarian cancer risk among 60,560 participants of the Nurses’ 
Health Study (NHS).
Materials and Methods
Study population
The Nurses’ Health Study (NHS) was established in 1976 with 121,700 US registered nurses 
aged 30–55 years [18]. Participants responded to baseline and biennial follow-up 
questionnaires providing detailed information on a variety of lifestyle factors and medical 
history. In this study, we excluded women who never provided information on periodontal 
bone loss, including those who died before 1998 (the first year in which periodontal bone 
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loss was queried; n=38,825). In addition, we excluded women with a prior history of cancer 
except non-melanoma skin cancer (n=11,763), bilateral oophorectomy (n=15,539), or 
menopause due to radiation (n=49), leading to a total of 60,560 eligible participants. This 
study was approved by the Institutional Review Board at Brigham and Women’s Hospital.
Case and exposure ascertainment
The primary exposure of interest in this study was self-reported periodontal bone loss. In 
1998, participants self-reported periodontal bone loss as none, mild, or moderate/severe; 
women who reported mild or moderate/severe were considered to have bone loss. In 2000, 
exposure information was updated based on self-reported periodontal bone loss in the 
previous 2 years (yes or no). A total of 60,560 women provided information on periodontal 
bone loss in 1998 and/or 2000.
Information on covariates was obtained from the biennial questionnaires, while data on 
nutritional factors was obtained from food frequency questionnaires that were updated every 
4 years. Women were first asked their number of natural teeth in 1992; this was updated in 
1996 and 2000. Number of root canals was asked in 2000, and duration and reason of 
antibiotic use was first assessed in 2004 and updated in 2008.
We identified 395 confirmed incident cases of ovarian cancer through biennial 
questionnaires from 2000 to 2012, or through death certificates. Deaths were identified 
through family members or the US Postal Service and the National Death Index. Medical 
and pathology reports were evaluated by a gynecological pathologist to confirm the 
diagnosis, and to obtain information on cancer grade, stage, invasiveness and histologic 
subtype; when medical records were unavailable, we linked to the appropriate tumor registry 
to obtain this information. Cases were considered rapidly fatal if the participant died within 
3 years of diagnosis.
Statistical analysis
Person-years were calculated from the baseline questionnaire return date (1998 or 2000, 
depending on when the participant first provided information on periodontal bone loss) to 
the date of ovarian or other cancer (except for non-melanoma skin cancer) diagnosis, 
bilateral oophorectomy, menopause due to radiation, death, or end of study follow-up (June 
2012), whichever occurred first. We used Cox proportional hazards models to estimate 
hazard ratios (HR) and 95% confidence intervals (CI) for periodontal bone loss (yes vs. no). 
In the multivariate model, we adjusted for known ovarian cancer risk factors including 
duration of OC use, number of pregnancies, duration of estrogen hormone therapy (HT), 
duration of estrogen and progesterone HT, tubal ligation and family history of ovarian 
cancer. We also considered potential confounding by smoking, menopausal status, body 
mass index (BMI), alternative healthy eating index (AHEI) [19], predicted vitamin D score 
[20], regularity of menstrual periods while menstruating, history of diabetes, physical 
activity, energy-adjusted alcohol, lactose and caffeine intake, current use of nonsteroidal 
anti-inflammatory drugs NSAIDs, antibiotic use, reason for use of antibiotics, median 
income of the participant’s neighborhood, number of natural teeth, osteoporosis, hip/arm 
fractures, wrist fractures and vertebral fractures; however none of these factors altered the 
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association and therefore were not included in the final multivariate model. Since use of 
antibiotics was ascertained for the first time in 2004, when adjusting for antibiotics we 
restricted the analysis to 2004 onward. In secondary analyses we also considered the 
association for exposure of number of teeth (restricted to periods >1998) and number of root 
canals (restricted to periods ≥2000). We performed stratified analysis by median BMI 
(<25.7 or ≥25.7), median age (<69 or ≥69), use of estrogen HT (ever or never), use of any 
HT (ever or never), history of diabetes (yes or no), current use of NSAIDs (non-use, use of 
aspirin only, use of non-aspirin NSAIDs only) and smoking status (never, past, current). 
Likelihood ratio tests were used to obtain the P-value for interaction. We also evaluated 
whether the association between periodontal bone loss and ovarian cancer differed by 
histological subtype, invasiveness and fatality using competing-risk Cox models [21]. All 
analysis was conducted using Statistical Analysis Software version 9.3 (SAS Institute, Cary, 
North Carolina).
Results
We confirmed 395 incident epithelial ovarian cancer cases over a total of 705,125 years of 
follow-up. The majority of tumors were serous/poorly differentiated (295), followed by 
endometrioid (37), mucinous (16), clear cell (9) and other (38). Participants suffering from 
periodontal bone loss were more likely to suffer from osteoporosis, to be current or past 
smokers and to consume more caffeine and alcohol than those with no bone loss (Table 1). 
Participants with periodontal bone loss had fewer natural teeth, and were more likely to have 
root canal procedures. While the total duration of antibiotic use was similar between two 
groups, there was more antibiotic use for dental reasons among participants with bone loss. 
Other characteristics did not differ substantially by periodontal bone loss status.
In age-adjusted models, participants with periodontal bone loss had a non-significant 14% 
lower risk of ovarian cancer (HR=0.86, 95% CI: 0.64–1.16) (Table 2). The results were 
similar after adjusting for known ovarian cancer risk factors (HR=0.86, 95% CI: 0.64–1.15). 
In the multivariate competing risk model, we observed a suggestively different association 
for serous/poorly differentiated versus non-serous tumors (p-heterogeneity=0.06). 
Periodontal bone loss was associated with a 24% lower risk of serous/poorly differentiated 
ovarian cancer compared to those with no bone loss (HR=0.76, 95% CI: 0.53–1.09), while 
there was no association for non-serous cancers (OR=1.56, 95% CI: 0.84–2.87). This 
difference reached statistical significance (p-heterogeneity=0.05) after adjusting for 
smoking, which is differentially associated with histologic subtypes [22]. There was no 
difference in association between invasive and borderline cancers (p-heterogeneity=0.28), or 
between rapidly fatal and less aggressive cases (p-heterogeneity=0.86).
Periodontal bone loss was suggestively more strongly inversely associated with ovarian 
cancer risk in women younger than 69 years (HR=0.60, 95%: CI: 0.36–0.98), but not in 
those older than 69 (HR=1.09, 95%: CI: 0.75–1.58), although the difference did not reach 
statistical significance (p-heterogeneity=0.06). A similar result was observed when 
considering only serous cancers (HR: 0.52, 95% CI: 0.28–0.97 in women <69, HR: 0.96, 
95% CI: 0.61–1.49 in women 69 years). Associations were similar by current use of 
NSAIDs, smoking, diabetes, BMI or HT use (p-heterogeneity>0.11; data not shown).
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There was no association between the number of root canals and risk of ovarian cancer (HR: 
1.00, 95% CI: 0.79–1.27 for women with 1–4 root canals, and HR: 1.24, 95% CI: 0.83–1.85 
for women with ≥5 root canals, compared to no root canals). Further, compared to women 
with 25–32 natural teeth, risk of ovarian cancer was similar in women with 0 (HR: 0.75, 
95% CI: 0.45–1.25), 1–10 (HR: 1.11, 95% CI: 0.74–1.67), 11–16 teeth (HR: 0.91, 95% CI: 
0.57–1.46) and 17–24 teeth (HR: 0.86, 95% CI: 0.65–1.13).
Discussion
In this first report of association between periodontal bone loss and risk of ovarian cancer, 
contrary to our hypothesis, we did not observe increased risk of ovarian cancer among 
women with periodontal bone loss. Our results support a possible inverse association for 
women <69 years old and for serous/poorly differentiated tumors. We did not observe an 
association with ovarian cancer for other markers of dental health, including number of root 
canals and number of natural teeth, possibly because these factors are acute, or can be 
caused by dental issues besides periodontitis.
While these observed inverse associations could be due to chance, there are several other 
possible explanations for this observation. Periodontitis and ovarian cancer share several 
well established etiological factors, such as OC or HT use [23, 24], and less established 
ovarian cancer risk factors such as smoking, coffee and alcohol use, unhealthy eating 
patterns and diabetes [25, 26]. Given that the risk estimates were essentially unchanged 
when adjusting for these factors, this is not a likely explanation for observed results. 
Alternatively, periodontal bone loss might reflect a more general bone loss due to 
osteoporosis. Low estrogen levels are characteristic of osteoporosis [27] while higher levels 
of endogenous estrogen might be associated with an increased risk of ovarian cancer [4]. 
However, studies on the association between endogenous estrogen and ovarian cancer risk 
are equivocal. Furthermore, adjusting for osteoporosis, or fractures that might be 
consequences of osteoporosis, did not change our estimate.
Another possibility is that medications used to treat periodontitis could be associated with a 
reduced risk of ovarian cancer. Non-surgical treatments for periodontal bone loss include 
antibacterial mouthwashes and antibiotics. While there are no data on association between 
antibiotic use and ovarian cancer risk, one might speculate that prolonged antibiotic use 
could potentially have a protective role, since some bacterial infections such as pelvic 
inflammatory disease have been associated with increased risk of ovarian cancer [28]. 
Adjusting for antibiotic use in our study did not change the estimate, although our ability to 
adjust for antibiotic use was restricted to periods after 2004, and therefore only to women 
older than 69, an age group for which the association was no longer significant.
It has been shown that adults with periodontitis have increased salivary levels of MUC1 
[29], a membrane-bound, high molecular weight protein expressed by many types of normal 
epithelial cells at low levels, and at high levels in several epithelial cancers, including breast 
and ovarian cancer [30]. MUC1 is also expressed in salivary glands and in oral epithelium 
[31], and it has been proposed to be up-regulated as a host response to chronic infection with 
specific oral pathogens [32]. Direct stimulation of oral cell line KB with Porphyromonas 
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gingivalis, one of the major pathogens involved in periodontitis, led to increased expression 
of MUC1 [32]. Indirectly, P. gingivalis and other periodontal pathogens Actinobacillus 
actinomycetemcomitans and Candida albicans, can increase production of IL-6 and IFN-
gamma [33, 34], leading to MUC1 up-regulation in oral KB cells [32]. It has been shown 
that conditions that involve increased expression of MUC1, such as pregnancy and 
breastfeeding, are associated with increased levels of circulating anti-MUC1 antibodies [35, 
36]. Anti-MUC1 antibodies have been suggestively associated with a decreased risk of 
ovarian cancer [37], possibly because they could be eliminating ovarian cancer cells that 
express MUC1 [35]. Although there are no direct studies of this, it is possible that the 
salivary increase in MUC1 due to periodontitis could lead to increased levels of anti-MUC1 
antibodies, which in turn may influence ovarian cancer risk.
We only observed a significant inverse association in women <69 years old. Interestingly, in 
the study of circulating anti-MUC1 antibodies referenced above, the association was only 
observed among women <64 years [37]. This could be possibly due to the phenomenon of 
immunosenescence, or aging of immune system, where antibodies decrease with age and 
time since antigen presentation [38]. In our secondary analysis we equally observed a 
suggestion of different associations between periodontal bone loss and ovarian cancer in 
women younger than 64 (HR: 0.52, 95% CI: 0.25–1.09) than in those older than 64 (HR: 
0.96, 95% CI 0.70–1.33), even though the difference did not reach statistical significance (p-
heterogeneity=0.15) due to small number of cases among women younger than 64.
Our study has several limitations. There is currently no standardized measure for 
periodontitis in epidemiological research. Several studies have used tooth loss as a marker 
for periodontitis. However, tooth loss may not be an appropriate marker for periodontitis 
since in people above 45 years of age periodontitis accounts for approximately half of tooth 
loss cases, while dental caries accounts for the rest [8]. Self-reported periodontitis was 
compared with radiographic bone loss measurement among non-dentist participants of the 
Health Professionals Study (HPFS). The positive predictive value for self-reported 
periodontitis with bone loss ranged from 71.8 to 83.1%, and the negative predictive value 
ranged from 68.7 to 73.9% [39]. Even though a similar validation study has not been 
conducted in the NHS, our participants are of similar demographic characteristics, consisting 
of non-dentist, medically trained professionals, and the validity of self-reported bone loss is 
likely to be comparable. While self-reported periodontal bone loss likely has some 
misclassification, it is likely to be non-differential, and thus would bias the estimate toward 
the null. Due to relatively small number of non-serous cancers, we were not able to 
separately evaluate association between periodontal bone loss and endometrioid, mucinous 
or clear cell carcinoma, which could perhaps give further insight into underlying 
mechanisms of this association. Since the majority of participants were menopausal in 1998, 
we were unable to evaluate this association among premenopausal women.
In summary, this is the first report of association between periodontal bone loss, as a marker 
for periodontitis, and ovarian cancer. Our results do not support that periodontal bone loss 
increases risk of ovarian cancer. However, given the unexpected possible inverse association 
in some subgroups, this exposure should be further investigated in independent populations.
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Table 1
Characteristics of participants by periodontal bone loss status in 2004
Periodontal bone loss
No bone loss (n=43,957) Bone loss (n=7,505)
Means (SD)
Age (years)a 69.3 (7.1) 69.6 (6.8)
Body mass index, kg/m2 26.6 (5.4) 26.2 (5.2)
Lactose, g/day 15.7 (11.5) 15.8 (11.7)
Caffeine, g/day 134.4 (127.1) 150.7 (136.8)
Alcohol, g/day 5.2 (10.0) 6.4 (11.4)
Alternative healthy eating index 56.1 (11.3) 56.7 (11.2)
Vitamin D prediction score 3.4 (3.7) 3.8 (3.7)
Physical activity, MET-hrs/week 20.1 (24.2) 20.3 (23.9)
OC use (months) 24.8 (40.9) 26.6 (42.8)
Estrogen HT (months) 24.7 (59.5) 24.7 (59.0)
Estrogen and progesterone HT (months) 30.3 (50.5) 32.8 (52.0)
Duration of antibiotic use (weeks) 17.9 (68.1) 18.8 (70.8)
Percentages
Postmenopausal 100 100
Tubal ligation 21 22
Parous 95 94
Menstrual period regularity
 Very regular 53 54
 Usually regular 19 19
 Usually irregular 9 9
 Very irregular 3 3
Family history of ovarian cancer 5 5
Smoking status
 Never smoker 47 30
 Past smoker 45 56
 Current smoker 7 13
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Periodontal bone loss
No bone loss (n=43,957) Bone loss (n=7,505)
Number of natural teeth
 0 natural teeth 5 6
 1–10 natural teeth 6 8
 11–16 natural teeth 5 7
 17–24 natural teeth 19 23
 25–32 natural teeth 66 57
Number of root canals
 0 39 30
 1–4 54 58
 >5 7 12
Diabetes 11 11
Osteoporosis 30 39
Hip/arm fractures 7 8
Wrist fractures 9 10
Vertebral fractures 4 6
Current NSAID use,
 Non-users 27 26
 Aspirin only 34 35
 Non-aspirin NSAID only 14 14
Use of antibiotics for dental reason 17 27
aValue is not age adjusted
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Table 2
Association between periodontal bone loss and ovarian cancer risk in the Nurses’ Health Study (1998–2012)
Number of cases No periodontal bone loss
HR (95% CI)
Periodontal bone loss
HR (95% CI)
p-heterogeneity
Age-adjusted, all cancersa 395 1.00 (ref) 0.86 (0.64–1.16)
Multivariate-adjusted, all cancersa,b 395 1.00 (ref) 0.86 (0.64–1.15) n/a
Serous cancersc 295 1.00 (ref) 0.76 (0.53–1.09)
Non-serous cancersc,d 62 1.00 (ref) 1.56 (0.84–2.87) 0.06
Age <69 yearsa,b 181 1.00 (ref) 0.60 (0.36–0.98)
Age ≥69 yearsa,b 214 1.00 (ref) 1.09 (0.75–1.58) 0.06
aCox proportional hazard model
bAdjusted for age, OC use (continuous in months), tubal ligation, family history of ovarian cancer, parity (continuous), duration of estrogen HT 
(continuous in months), duration of estrogen and progesterone HT (continuous in months)
cCompeting risk model adjusted for age, parity (both unconstrained), tubal ligation, family history of ovarian cancer, OC use in months (all 3 
constrained)
d
Mucinous, endometrioid and clear cell
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